These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

355 related items for PubMed ID: 23137529

  • 21. Is oxaliplatin combined with weekly bolus 5-fluorouracil and leucovorin an option for stage II and III colon cancer?
    Twelves C.
    Nat Clin Pract Oncol; 2008 Feb; 5(2):72-3. PubMed ID: 18030299
    [No Abstract] [Full Text] [Related]

  • 22. Association of oxaliplatin-containing adjuvant duration with post-treatment fall-related injury and fracture in patients with stage III colon cancer: a population-based retrospective cohort study.
    Sue-Chue-Lam C, Brezden-Masley C, Sutradhar R, Yu AYX, Baxter NN.
    BMC Cancer; 2024 Jul 22; 24(1):878. PubMed ID: 39039514
    [Abstract] [Full Text] [Related]

  • 23. Adjuvant therapy of colon cancer: current status and future directions.
    Chung KY, Saltz LB.
    Cancer J; 2007 Jul 22; 13(3):192-7. PubMed ID: 17620769
    [Abstract] [Full Text] [Related]

  • 24. Comparison of adverse events during 5-fluorouracil versus 5-fluorouracil/oxaliplatin adjuvant chemotherapy for stage III colon cancer: a population-based analysis.
    Sanoff HK, Carpenter WR, Freburger J, Li L, Chen K, Zullig LL, Goldberg RM, Schymura MJ, Schrag D.
    Cancer; 2012 Sep 01; 118(17):4309-20. PubMed ID: 22294436
    [Abstract] [Full Text] [Related]

  • 25. Racial/ethnic disparities in the adjuvant chemotherapy of locally advanced colon cancer patients.
    Zhong X, Guo Z, Gao P, Song Y, Sun J, Chen X, Sun Y, Wang Z.
    J Surg Res; 2018 Aug 01; 228():27-34. PubMed ID: 29907221
    [Abstract] [Full Text] [Related]

  • 26. Adjuvant chemotherapy for localised colon cancer. Fluorouracil + folinic acid for node-positive, non-metastatic disease.
    Prescrire Int; 2011 Feb 01; 20(113):46-9. PubMed ID: 21488594
    [Abstract] [Full Text] [Related]

  • 27. Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin.
    Yothers G, O'Connell MJ, Lee M, Lopatin M, Clark-Langone KM, Millward C, Paik S, Sharif S, Shak S, Wolmark N.
    J Clin Oncol; 2013 Dec 20; 31(36):4512-9. PubMed ID: 24220557
    [Abstract] [Full Text] [Related]

  • 28. Patterns of adjuvant chemotherapy use in a population-based cohort of patients with resected stage II or III colon cancer.
    Abrams TA, Brightly R, Mao J, Kirkner G, Meyerhardt JA, Schrag D, Fuchs CS.
    J Clin Oncol; 2011 Aug 20; 29(24):3255-62. PubMed ID: 21768462
    [Abstract] [Full Text] [Related]

  • 29. Stage III Colon Cancer: The Individualized Strategy of Adjuvant Chemotherapy for Aged Under and Over 70.
    Lu CS, Chang PY, Chen YG, Chen JH, Wu YY, Ho CL.
    PLoS One; 2015 Aug 20; 10(9):e0138632. PubMed ID: 26382962
    [Abstract] [Full Text] [Related]

  • 30. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial.
    Tournigand C, André T, Bonnetain F, Chibaudel B, Lledo G, Hickish T, Tabernero J, Boni C, Bachet JB, Teixeira L, de Gramont A.
    J Clin Oncol; 2012 Sep 20; 30(27):3353-60. PubMed ID: 22915656
    [Abstract] [Full Text] [Related]

  • 31. A meta-analysis of chemotherapy regimen fluorouracil/leucovorin/oxaliplatin compared with fluorouracil/leucovorin in treating advanced colorectal cancer.
    Chen ML, Fang CH, Liang LS, Dai LH, Wang XK.
    Surg Oncol; 2010 Mar 20; 19(1):38-45. PubMed ID: 19345093
    [Abstract] [Full Text] [Related]

  • 32. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06.
    Lembersky BC, Wieand HS, Petrelli NJ, O'Connell MJ, Colangelo LH, Smith RE, Seay TE, Giguere JK, Marshall ME, Jacobs AD, Colman LK, Soran A, Yothers G, Wolmark N.
    J Clin Oncol; 2006 May 01; 24(13):2059-64. PubMed ID: 16648506
    [Abstract] [Full Text] [Related]

  • 33. Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy.
    Zaanan A, Fléjou JF, Emile JF, Des GG, Cuilliere-Dartigues P, Malka D, Lecaille C, Validire P, Louvet C, Rougier P, de Gramont A, Bonnetain F, Praz F, Taïeb J.
    Clin Cancer Res; 2011 Dec 01; 17(23):7470-8. PubMed ID: 21998335
    [Abstract] [Full Text] [Related]

  • 34. A randomised phase III intergroup trial comparing high-dose infusional 5-fluorouracil with or without folinic acid with standard bolus 5-fluorouracil/folinic acid in the adjuvant treatment of stage III colon cancer: the Pan-European Trial in Adjuvant Colon Cancer 2 study.
    Köhne CH, Bedenne L, Carrato A, Bouché O, Popov I, Gaspà L, Valladares M, Rougier P, Gog C, Reichardt P, Wils J, Pignatti F, Biertz F.
    Eur J Cancer; 2013 May 01; 49(8):1868-75. PubMed ID: 23571150
    [Abstract] [Full Text] [Related]

  • 35. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?
    Gill S, Loprinzi CL, Sargent DJ, Thomé SD, Alberts SR, Haller DG, Benedetti J, Francini G, Shepherd LE, Francois Seitz J, Labianca R, Chen W, Cha SS, Heldebrant MP, Goldberg RM.
    J Clin Oncol; 2004 May 15; 22(10):1797-806. PubMed ID: 15067028
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1.
    André T, Quinaux E, Louvet C, Colin P, Gamelin E, Bouche O, Achille E, Piedbois P, Tubiana-Mathieu N, Boutan-Laroze A, Flesch M, Lledo G, Raoul Y, Debrix I, Buyse M, de Gramont A.
    J Clin Oncol; 2007 Aug 20; 25(24):3732-8. PubMed ID: 17704423
    [Abstract] [Full Text] [Related]

  • 38. Innovative chemotherapies for stage III colon cancer: a cost-effectiveness study.
    Koperna T, Semmler D.
    Hepatogastroenterology; 2003 Aug 20; 50(54):1903-9. PubMed ID: 14696430
    [Abstract] [Full Text] [Related]

  • 39. Benefit of Oxaliplatin in Stage III Colon Cancer According to IDEA Risk Groups: Findings from the ACCENT Database of 4934 Patients.
    Margalit O, Boursi B, Rakez M, Thierry A, Yothers G, Wolmark N, Haller DG, Schmoll HJ, Shi Q, Shacham-Shmueli E, de Gramont A.
    Clin Colorectal Cancer; 2021 Jun 20; 20(2):130-136. PubMed ID: 33775561
    [Abstract] [Full Text] [Related]

  • 40. A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer.
    Schippinger W, Samonigg H, Schaberl-Moser R, Greil R, Thödtmann R, Tschmelitsch J, Jagoditsch M, Steger GG, Jakesz R, Herbst F, Hofbauer F, Rabl H, Wohlmuth P, Gnant M, Thaler J, Austrian Breast and Colorectal Cancer Study Group.
    Br J Cancer; 2007 Oct 22; 97(8):1021-7. PubMed ID: 17895886
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.